FDA Approves NUWIQ to Treat Hemophilia A

Photo of blood sample vials

The U.S. Food and Drug Administration ha approved Octapharma’s NUWIQ, antihemophilic factor (recombinant), an intravenous therapy for adults and children living with hemophilia A.